Follow The Filings

REPL Replimune Group Inc.

Health Care, filed as REPLIMUNE GROUP INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Bought by 1 manager in 2026 Q2

  • 2 Owners
  • Max 1.4%
  • $15M
  • 1 new 1 small

In 2026 Q2 James Silverman opened a position in Replimune Group.

Who owns this now

Largest portfolio weights among holders, up to 1.4% (James Silverman, Opaleye Management). Not free-float ownership.

  1. James Silverman New 1.4%

Who owns REPL

Sorted by value, long equity only, as of 2026 Q2.

History
James Silverman, Opaleye Management 1.4% New 1.4% 1,384,993 $15M History
Murray Stahl, Horizon Kinetics Asset Management <0.01% Small trim −4.6% 12,584 $139K History

2 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by REPL's executives, directors and 10% owners in the last 12 months, from their Form 4s

All REPL insider trades
  • None no insider bought on the open market
  • $33K sold by 1 insider outside a trading plan
  • $274K sold by 2 insiders under 10b5-1 plans
  1. Christopher Sarchi Chief Commercial Officer
    Planned sale
    $111K 12,000 shares at $9.24 6.2% of stake
    Traded Jun 1 Filed Jun 3
    ↗
  2. Christopher Sarchi Chief Commercial Officer
    Planned sale
    $52K 6,500 shares at $8.01 4.1% of stake
    Traded Apr 2 Filed Apr 6
    ↗
  3. Kapil Dhingra Director
    Sale
    $33K 3,169 shares at $10.40 100% of stake
    Traded Dec 9, 2025 Filed Dec 11, 2025
    ↗
  4. Sushil Patel CEO
    Planned sale
    $111K 10,000 shares at $11.13 2.9% of stake
    Traded Dec 2, 2025 Filed Dec 4, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 13 sales to cover taxes, 11 stock grants, 2 gifts, and 1 option exercise.

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
8-K 5.03,5.07,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13D/A — Filing Doc
8-K/A 8.01,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
424B5 Filing Doc
8-K 8.01,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
8-K 8.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 8.01,9.01 Filing Doc
8-K 7.01,9.01 Filing Doc
DEF 14A FORM -DEF 14A Filing Doc
DEFA14A Filing Doc
8-K 2.02,9.01 Filing Doc
10-K Filing Doc
8-K 7.01,9.01 Filing Doc
8-K 7.01,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 7.01,8.01,9.01 Filing Doc

Source: SEC EDGAR submissions, updated 5 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025 FY2026
Net income -$174.28M -$215.79M -$247.3M -$313.94M

Balance sheet

Metric FY2023 FY2024 FY2025 FY2026
Total current assets $592.6M $433.67M $495.88M $279.12M
Total non-current assets * $53.99M $54.06M $55.45M $53.27M
Total assets $646.59M $487.72M $551.33M $332.39M
Total current liabilities $33.82M $40.44M $62.36M $58.23M
Total non-current liabilities * $57.47M $72.78M $73.12M $108M
Total equity $555.29M $374.51M $415.84M $166.16M

Cash flow

Metric FY2023 FY2024 FY2025 FY2026
Cash from operations -$128.05M -$185.47M -$192.25M -$280.34M
Cash from investing -$142.5M $97.2M -$23.8M $310.84M
Cash from financing $311.3M $16.28M $252.4M $66.29M
Net change in cash $40.64M -$72.07M $36.66M $97.9M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.